Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial
Détails
Télécharger: REF.pdf (724.47 [Ko])
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
Etat: Public
Version: Final published version
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_27096E952FE6
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Treatment of gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial
Périodique
Journal of Infectious Diseases
ISSN
0022-1899 (Print)
Statut éditorial
Publié
Date de publication
08/1988
Volume
158
Numéro
2
Pages
312-9
Langue
anglais
Notes
Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't --- Old month value: Aug
licence nationale
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't --- Old month value: Aug
licence nationale
Résumé
In a randomized, double-blind, multicenter trial we compared the efficacy of a preparation of human IgG antibody to Escherichia coli J5 (J5-IVIG) with that of a standard IgG preparation (IVIG) for the treatment of gram-negative septic shock. At study entry, patients received a single intravenous dose of 200 mg/kg of body weight (maximal dose, 12 g) of either J5-IVIG or IVIG. Of the 100 patients randomized, 71 (30 receiving J5-IVIG and 41 receiving IVIG) had a documented gram-negative infection. Mortality from gram-negative septic shock was 50% (15 of 30) in J5-IVIG recipients and 49% (20 of 41) in IVIG recipients. In addition, treatment with J5-IVIG did not reduce the number of systemic complications of shock and did not delay the occurrence of death due to septic shock. Thus we conclude that J5-IVIG was not superior to IVIG in reducing mortality or in reversing gram-negative septic shock.
Mots-clé
Adolescent
Adult
Aged
Child
Clinical Trials
Double-Blind Method
Escherichia coli/*immunology
Female
Gram-Negative Bacteria
Humans
*Immunization, Passive
Immunoglobulin G/immunology/*therapeutic use
Immunoglobulins, Intravenous
Male
Middle Aged
Prospective Studies
Random Allocation
Sepsis/complications/therapy
Shock, Septic/complications/mortality/*therapy
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/01/2008 14:28
Dernière modification de la notice
14/02/2022 8:54